For families facing diffuse midline glioma, rapid progression and scarce options have long defined the journey. Hear how following the biology, learning from outliers, and uniting researchers, clinicians, advocates, and families led to meaningful progress and a new therapeutic option for patients with H3 K27M‑mutant disease.

Jazz has a longstanding commitment to sleep medicine through vital partnerships with notable organizations in the community. Collaborations with patient advocacy groups are crucial for understanding patient needs, raising awareness of comorbidities through educational resources and improving comprehensive care for people living with narcolepsy or idiopathic hypersomnia.

Across rare disease, patients continue to navigate serious conditions with few effective treatments. Hear from Renee Gala, President and CEO, on how we are sharpening our strategic focus to drive innovation and strengthen our commitment to delivering meaningful impact for patients and their families.

People diagnosed with locally advanced/metastatic HER2-positive gastroesophageal adenocarcinoma continue to face limited treatment options with the need to improve outcomes. Discover why innovation in the first-line setting remains essential to improving care.

Epilepsy is one of the most common neurological diseases in the world. While many treatments are available, there remains a significant unmet need among adult and pediatric patients who experience treatment-resistant seizures. Read more about how we are continuing to shine a light on the real-world burden associated with living with rare, treatment-resistant epileptic conditions.

For years, relapse after initial therapy has defined the outlook for people with extensive-stage small cell lung cancer (ES-SCLC). The FDA approval of a first-line maintenance combination regimen marks an important step forward, building on past progress and creating the possibility of longer-lasting benefit for patients and families.